Stock KYOWA HAKKO KIRIN CO LTD
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

Kyowa Hakko Kirin Co Ltd Stock BOERSE MUENCHEN

Equities

Pharmaceuticals

End-of-day quote BOERSE MUENCHEN
Other stock markets
- EUR - Intraday chart for Kyowa Hakko Kirin Co Ltd
Apr. 08 U.S. FDA declines to approve Supernus' drug-device combination for Parkinson's disease RE
Apr. 03 Kyowa Kirin Buys Back 4 Billion Yen Worth of Shares in March MT

Financials

Sales 2024 * 471B 3.01B 2.81B Sales 2025 * 483B 3.09B 2.88B Capitalization 1,407B 9B 8.4B
Net income 2024 * 66.51B 426M 397M Net income 2025 * 72.93B 467M 435M EV / Sales 2024 * 2.29 x
Net cash position 2024 * 330B 2.11B 1.97B Net cash position 2025 * 361B 2.31B 2.15B EV / Sales 2025 * 2.17 x
P/E ratio 2024 *
21 x
P/E ratio 2025 *
19.1 x
Employees -
Yield 2024 *
2.21%
Yield 2025 *
2.31%
Free-Float 45.89%
More Fundamentals * Assessed data

Latest news about Kyowa Hakko Kirin Co Ltd

U.S. FDA declines to approve Supernus' drug-device combination for Parkinson's disease RE
Kyowa Kirin Buys Back 4 Billion Yen Worth of Shares in March MT
Tranche Update on Kyowa Kirin Co., Ltd.'s Equity Buyback Plan announced on February 7, 2024. CI
Japanese Shares Slip into Red Amid Profit-Taking; Tokyo Inflation Eyed MT
Kyowa Kirin to Allocate Over 84,000 Treasury Shares as Director, Officer Compensation MT
Kyowa Kirin's gene therapy most expensive US drug with $4.3 million price tag RE
US approves first gene therapy for children with rare genetic disease RE
US approves first gene therapy for rare genetic disease RE
Kyowa Kirin Co., Ltd. to Present Phase 2B Post-Hoc Analysis and Symposium At the American Academy of Dermatology Annual Meeting 2024 CI
Kyowa Kirin Buys Back Nearly 3 Billion Yen of Shares MT
China Deflation, Bank of Japan Roil Asian Stock Markets MT
Japan's Nikkei closes at 34-year peak on dovish BOJ; tech shares soar RE
Japan's Nikkei leaps to 2-week high on tech stocks, yen boost RE
BridgeBio Pharma Unit to Grant Kyowa Kirin License for Infigratinib in Japan MT
Kyowa Kirin's Profit Up 52% in Fiscal 2023 MT
More news

Analyst Recommendations on Kyowa Hakko Kirin Co Ltd

Jefferies Adjusts Kyowa Kirin’s Price Target to 3,000 Yen From 3,600 Yen, Keeps at Buy MT
Jefferies Adjusts Kyowa Kirin's Price Target to 3,600 Yen From 3,900 Yen, Keeps at Buy MT
Nikkei 225 Down 1.5% on ECB Rate Hike, US CPI Outlook MT
MEI Pharma Says Treatment With Follicular Lymphoma Drug Candidate Shows Complete Response Rate of Over 35% in Mid-Stage Trial MT
Kyowa Hakko Kirin Co., Ltd. Provides Tax Rate Outlook for the Year 2018 CI
More recommendations

Press releases Kyowa Hakko Kirin Co Ltd

Kyowa Kirin to Present a Safety Meta-Analysis of NOURIANZ (istradefylline) and Other Parkinson's Disease Add-On Therapies AQ
First Interim Analysis of PROSPER Study Details Patient-Reported Symptom Burden of Mycosis Fungoides and Sézary Syndrome BU
Kyowa Kirin Will Present Phase 2b Post-hoc Analysis and Symposium at the American Academy of Dermatology Annual Meeting 2024 AQ
Kyowa Kirin : Partial Corrections to “Notice of Convocation of the 101st Ordinary General Meeting of Shareholders” (0B) PU
Kyowa Kirin Co., Ltd - Notice regarding Completion of Share Acquisition of Orchard Therapeutics plc AQ
More press releases

News in other languages on Kyowa Hakko Kirin Co Ltd

EEUU aprueba la primera terapia de genes para niños con una rara enfermedad hereditaria
MÄRKTE ASIEN/Tokio sehr fest auf 34-Jahreshoch - Softbank mit Kurssprung
Kyowa Kirin schließt erfolgreich die Übernahme von Orchard Therapeutics ab, einem Weltmarktführer für Gentherapie bei seltenen Krankheiten
LATE BRIEFING - Unternehmen und Märkte
MIDDAY BRIEFING - Unternehmen und Märkte
More news

Managers and Directors - Kyowa Hakko Kirin Co Ltd

Managers TitleAgeSince
Motohiko Kawaguchi DFI
 Director of Finance/CFO - 86-03-31
Masashi Miyamoto PSD
 President 64 85-03-31
Takeyoshi Yamashita CTO
 Chief Tech/Sci/R&D Officer 62 10-03-31
Members of the board TitleAgeSince
Takashi Oyamada BRD
 Director/Board Member 68 21-02-28
Yoshihisa Suzuki BRD
 Director/Board Member 68 22-02-28
Toshifumi Mikayama BRD
 Director/Board Member 66 08-09-30
More insiders

Company Profile

Kyowa Kirin Co., Ltd. specializes in the development, manufacturing and marketing of pharmaceutical and biochemical products. Net sales break down by source of revenue as follows: - sales of pharmaceutical products (92.6%): prescription products for anemia, cancers, immune and nephrology diseases treatment; - sales of licenses (7.4%). At the end of 2021, the group had 3 production sites located in Japan (2) and China. Net sales break down geographically as follows: Japan (60.9%), Asia (9%), Americas (16.3%) and Europe (13.8%).
Sector
Pharmaceuticals
Calendar
2024-05-06 - Q1 2024 Earnings Release
Related indices
Nikkei 225
More about the company

Sector Specialty & Advanced Pharmaceuticals

1st Jan change Capi.
MERCK KGAA Stock Merck KGaA
+4.06% 70.44B
SK BIOPHARMACEUTICALS CO., LTD. Stock SK Biopharmaceuticals Co., Ltd.
-14.44% 4.75B
SHENYANG XINGQI PHARMACEUTICAL CO.,LTD. Stock Shenyang Xingqi Pharmaceutical Co.,Ltd.
+41.60% 4.5B
YUHAN CORPORATION Stock Yuhan Corporation
+5.96% 3.85B
INDIVIOR PLC Stock Indivior PLC
+23.46% 2.38B
BETTA PHARMACEUTICALS CO., LTD. Stock Betta Pharmaceuticals Co., Ltd.
-19.32% 2.34B
CHANGCHUN BCHT BIOTECHNOLOGY CO. Stock Changchun BCHT Biotechnology Co.
-27.04% 2.2B
SHANGHAI SHYNDEC PHARMACEUTICAL CO., LTD. Stock Shanghai Shyndec Pharmaceutical Co., Ltd.
+7.97% 1.96B
VELOXIS PHARMACEUTICALS A/S Stock Veloxis Pharmaceuticals A/S
-0.50% 1.64B
Specialty & Advanced Pharmaceuticals
  1. Stock Market
  2. Equities
  3. 4151 Stock
  4. Stock